Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Marius Rademaker; Karen Agnew; Megan Andrews; Christopher Baker; Peter Foley; Kurt Gebauer; Monisha Gupta; Diana M Rubel; Colin Somerville; John Sullivan; Li-Chuen Wong

doi:10.1111/ajd.13141

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Australas J Dermatol. 2020 Feb;61(1):9-22. doi: 10.1111/ajd.13141. Epub 2019 Sep 16.

Authors

Marius Rademaker¹, Karen Agnew^{2

3}, Megan Andrews⁴, Christopher Baker^{5

6}, Peter Foley^{5

6}, Kurt Gebauer^{7

8}, Monisha Gupta^{9

10

11}, Diana M Rubel^{12

13}, Colin Somerville¹⁴, John Sullivan¹⁵, Li-Chuen Wong¹⁶

Affiliations

¹ Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand.
² Dermatology Department, Greenlane Clinical Centre, Auckland, New Zealand.
³ Starship Children's Hospital, Auckland, New Zealand.
⁴ Woolloongabba, Queensland, Australia.
⁵ St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
⁶ Skin & Cancer Foundation Inc., Carlton, Victoria, Australia.
⁷ University of Western Australia, Perth, Western Australia, Australia.
⁸ Probity Medical Research, Freemantle, Western Australia, Australia.
⁹ Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁰ The Skin Hospital, Darlinghurst, New South Wales, Australia.
¹¹ University of New South Wales, Sydney, New South Wales, Australia.
¹² Woden Dermatology, Phillip, Australian Capital Territory, Australia.
¹³ Australian National University, Canberra, Australian Capital Territory, Australia.
¹⁴ The Allergy West Clinic - Immunology, Perth, Western Australia, Australia.
¹⁵ Kingsway Dermatology, Miranda, New South Wales, Australia.
¹⁶ The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

PMID: 31529493
DOI: 10.1111/ajd.13141

Abstract

With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

Keywords: atopic dermatitis; atopic eczema; azathioprine; biologic therapies; ciclosporin; corticosteroids; methotrexate; mycophenolate; second-line therapy; small molecules; systemic treatment.

Publication types

Review

MeSH terms

Adolescent
Adult
Anti-Bacterial Agents / therapeutic use
Australia
Dermatitis, Atopic / drug therapy*
Dermatologic Agents / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
New Zealand
Young Adult

Substances

Anti-Bacterial Agents
Dermatologic Agents
Immunosuppressive Agents

Grants and funding

AbbVie Pty Ltd (Australia)